Susan Abushakra
Chief Medical Officer Alzheon
Seminars
Tuesday 3rd February 2026
Panel Discussion: Deciphering the Landscape of Emerging Neurodegenerative Fluid Markers Beyond p-tau & α-Synuclein
9:00 am
- GBA, LRRK2, and TREM2: Where do these emerging targets stand in terms of measurable, scalable biomarkers?
- What should define a ‘clinically useful’ biomarker when translatability remains uncertain?
- How do we ensure fluid biomarkers reflect causal disease biology rather than downstream noise?
Wednesday 4th February 2026
Oral Amyloid Oligomer Inhibition with ALZ-801: A Precision Medicine Approach for Early Alzheimer’s Disease
4:00 pm
- Targeting amyloid oligomer formation through an oral small molecule mechanism, avoiding ARIA-related safety concerns observed with antibody approaches, delivering a safer, scalable treatment option for early AD patients, including highrisk APOE4 carriers
- Presenting clinical findings from Phase 2 and 3 studies, demonstrating beneficial cognitive and functional outcomes in early disease, supporting ALZ-801 as a potential first-in-class oral disease-modifying therapy
- Positioning ALZ-801 in the evolving AD treatment landscape, offering a differentiated therapeutic pathway for APOE4 carriers, expanding precision medicine opportunities while complementing or replacing antibody-based strategies
